⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546913 | 1.00 | — | — | |
| SCHEMBL18474377 | 1.00 | — | — | |
| Phosphine SCHEMBL27998527 | 0.98 | NOS2 (0.50) | — | |
| Methane SCHEMBL27493565 | 0.98 | NOS2 (0.50) | — | |
| Hydrochloric Acid SCHEMBL5418246 | 0.98 | NOS2 (0.50) | — | |
| Ammonia Solution, Strong SCHEMBL27413104 | 0.98 | NOS2 (0.50) | — | |
| SCHEMBL840224 | 0.98 | NOS2 (0.50) | — | |
| Ethane SCHEMBL27994756 | 0.96 | NOS2 (0.48) | — | |
| Ammonia Solution, Strong SCHEMBL28000860 | 0.96 | NOS2 (0.48) | — | |
| Ammonia Solution, Strong SCHEMBL28838077 | 0.96 | NOS2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076062-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-03-19 | — | — | US | claimed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022185260-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-09-09 | — | — | WO | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2017023894-A1 | MTHFD2 INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20090076062-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-03-19 | — | — | US | disclosed |